XML 70 R13.htm IDEA: XBRL DOCUMENT
v3.22.4

Intangible assets | 12 Months Ended
--- | ---
Dec. 31, 2022
Intangible assets |
Intangible assets | 7.Intangible assets AC Immune’s acquired IPR&D asset is a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease. The asset is not yet ready for use until the asset obtains market approval. The carrying amount and net book value are detailed below: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | As of December 31, 2022 | ​ | As of December 31, 2021
​ |  | Gross |  | ​ |  | ​ |  | Gross |  | ​ |  | ​
​ | ​ | carrying | ​ | Accumulated | ​ | Net book | ​ | carrying | ​ | Accumulated | ​ | Net book
In CHF thousands | ​ | amount | ​ | amortization | ​ | value | ​ | amount | ​ | amortization | ​ | value
Acquired IPR&D asset | ​ | 50,416 |  | — |  | 50,416 |  | 50,416 |  | — |  | 50,416
Total intangible assets | ​ | 50,416 |  | — |  | 50,416 |  | 50,416 |  | — |  | 50,416
​ In accordance with IAS 36 Impairment of Assets, the IPR&D asset is reviewed at least annually for impairment by assessing the fair value less costs to sell (recoverable amount) and comparing this to the carrying value of the asset. The valuation is considered to be Level 3 in the fair value hierarchy in accordance with IFRS 13 Fair Value Measurement due to unobservable inputs used in the valuation. The Company has determined the IPR&D asset was not impaired as of December 31, 2022 and 2021, respectively. The key assumptions used in the valuation model in accordance with an income approach to determine the recoverable amount include observable and unobservable key inputs as follows:
| ● | Anticipated research and development costs;
| ● | Anticipated costs of goods and sales and marketing expenditures;
| ● | Probability of achieving clinical and regulatory development milestones in accordance with certain industry benchmarks;
| ● | Target indication prevalence and incidence rates;
| ● | Anticipated market share;
| ● | General commercialization expectations such as anticipated pricing and uptake;
| ● | Expected patent life and market exclusivity periods; and
| ● | Other metrics such as the tax rate.
The Company’s valuation model calculates the risk-adjusted, net cash flows through the projected period of market exclusivity across target sales regions. The Company uses a discount rate of 17% (15% for 2021), based on the assumed cost of capital for the Company over the forecast period. See “Note 6. Asset acquisition” for further details.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2021-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration